Which children with idiopathic short stature should receive growth hormone therapy?
Paul Czernichow
Correspondence Hopital Necker Enfants Malades, 149 rue de Sevres, Paris 75015, France
Email paul.czernichow@nck.aphp.fr
The use of growth hormone to treat children with idiopathic short stature remains an area of controversy. The author of this Viewpoint discusses the possible etiology of idiopathic short stature, the efficacy and safety of the treatment regimen, and which children with this condition should be selected for therapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
